Elan Drug Technologies develops and manufactures innovative pharmaceutical products that deliver clinically meaningful benefits to patients, using its extensive experience and proprietary drug technologies in partnership with pharmaceutical companies.

1. World’s Leading Drug Delivery Company General Presentation January 2011

4. Elan Drug Technologies has Solved the Delivery Challenges of more than 30 Marketed Products Since 2001, 12 products have been launched in the US using our technologies, making us the most productive drug technology company during this period. Here are a range of products launched incorporating our technologies - Acorda (Ampyra ® ) Janssen (Invega ® Sustenna ® ) Pfizer Strativa Pharmaceuticals

5. Successful collaborations with many of the world’s leading pharmaceutical companies. Successful collaborations with more than 30 of the world’s leading pharmaceutical companies for development and/or scale-up & manufacturing. Strong Partnering Capabilities Across the Pharma Sector

6. Robust Pipeline | 14 Products in Clinical Development 8 Products

7. Robust, Broad Platform of Validated Technologies Suite of validated, commercially launched, proprietary, technology driven solutions. Invega ® Sustenna ® Ampyra ®

9. NanoCrystal ® Technology | What is it? • Most dosage forms possible (e.g. oral, parenteral and nasal) • Increases oral bioavailability & reduces fed/fasted variability • Decreases time to onset of action • High drug loading possible (up to 30-40% active) • Combine with other technologies (e.g. controlled release) • Low viscosity liquid preparations • Potential for improved chemical stability compared to solutions • Uses standard pharmacopoeial materials A proprietary formulation and manufacturing approach for the delivery of poorly water- soluble drugs NanoCrystal ® technology involves reducing drug particles to the nanometer size. By reducing particle size, we increase the drug’s exposed surface area. We then stabilise the particles to maintain the formulation’s particle size.

11. Our Controlled Release Technology Platform Allows a Range of Release Profiles and Dosage Forms to be Engineered 23 products launched using our OCR technology platforms including Avinza ® , Cardizem ® SR and CD, Focalin XR ® , Ritalin ® LA, Verelan ® , Verelan ® PM, Naprelan ® Luvox CR ® , Zanaflex Capsules ® and Ampyra™. Other technologies developed by Elan Drug Technologies include PharmaZome ® technology and INDAS™ technology. SODAS ® - Spheroidal Oral Drug Absorption System IPDAS ® - Intestinal Protective Drug Absorption System CODAS ® - Chrono-therapeutic Oral Drug Absorption System PRODAS ® - Programmable Oral Drug Absorption System MXDAS ® - MatriX Drug Absorption System DUREDAS™ - DUal Release Drug Absorption System Combo IR, CR & Delayed Release profiles, reduction in peak-to-trough ratios Multi-particulate beads in a tablet , Intestinal protective Delivery profile designed to complement circadian pattern Controlled absorption over a period, targeted delivery to absorption sites Polymer blend to control absorption over a period, targeted delivery Bilayer tablet, IR or SR release of two drug components

15. Elan Drug Technologies Campus - Athlone, Ireland Athlone, Ireland Facility Located on 40 acres site, the facility has approximately 505,000 square feet of space. Operates under cGMP standards. FDA/EMA Licensed. Formulation through scale-up and full scale manufacturing. 10 different products are manufactured and/or packaged at this site at present. Manufactures product for US, European and Asian markets. The facility has an equipped capacity of 2 billion unit solid oral doses.

16. Elan Drug Technologies Facility - Gainesville, Georgia, USA Gainesville, GA, USA Facility Located on 148 acres of land, the facility has approximately 87,000 square feet of space. Includes 288 pallet vault built in accordance with DEA specifications. Operates under cGMP standards. Two-level facility . FDA/EMA/DEA Licensed. Formulation through scale-up and full scale manufacturing. 10 different products are manufactured and/or packaged at this site at present. Manufactures product for US, European and Asian markets. The facility has an equipped capacity of 500 million unit solid oral doses.